multiple myeloma
Conditions
Interventions
Lenalidomide 10-15mg/day (Day 1-21) p.o
Sponsors
National Defense Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who give written informed consent following sufficient explanation. 2. Patients who have been diagnosed as symptomatic multiple myeloma by the criteria of IMWG. 3. Patients who have measurable M protein or FLC in serum or urine. 4. Patients over 20 years old and not eligible for ASCT. 5. Female patients who are post menopause (patients older than one year from the last menstrual period), of the proper way of surgical contraception (birth control pill, contraceptives, etc.) and who have the intention of contraception during the lenalidmide therapy. Male patients who agree the appropriate method of contraception during the lenalidmide therapy. 6. Patients who have achieved the response more than PR in the initial treatment with bortezomib. There is no limitation on the period of response.
Exclusion criteria
Exclusion criteria: 1. Patients who are pregnant or lactating. 2. Patients who had been determined ineligible for any reason by physician. 3. Patients who have not achieved PR with bortezomib therapy as initial treatment. 4. Patients who progressed in disease status less than PR after the initial response.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best response rate | — |
Countries
Japan
Contacts
Public ContactShinichi Kobayashi
National Defense Medical College Division of Hematology
Outcome results
None listed